Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus

Abstract

Objectives: We aimed to investigate the effects of asprosin on diabetes with a focus on serum glucose, irisin, ghrelin, leptin levels and hepatic levels of triglycerides (TG), cholesterol, low-density lipoprotein (LDL). Methods: Asprosin (10 mg/kg) was administered intraperitoneally four times at 3-day intervals and then blood and hepatic parameters above mentioned were investigated in control and diabetic mice. Results: The administration of asprosin increased blood glucose level in healthy animals (p¼ .05) whereas it did not change blood glucose level in diabetic animals. In addition, while asprosin decreased irisin level and increased ghrelin level, it did not change leptin level in diabetic mice. Therewithal, asprosin decreased the increasing levels in hepatic TG, cholesterol, and LDL in diabetic mice. Conclusions: Our novel findings implicate that asprosin may be a target molecule in preventing the development and complications of diabetes.